SAN DIEGO, Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that the final five-year clinical data for high-risk patients ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...
SAN DIEGO -- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that 30-day outcomes for high- and intermediate-risk ...
SAN DIEGO (March 15, 2015) -- Five-year data suggest that the SAPIEN transcatheter heart valve is a feasible option for patients with severe aortic stenosis deemed to be at high risk for open-heart ...
SAN FRANCISCO -- Sapien 3 transcatheter aortic valves will probably last 25 years when implanted right, bench testing showed. After 1 billion cycles of accelerated wear testing with a pulsatile flow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results